GARDP Welcomes G7 Support for its Pivotal Work to Counter Antimicrobial Resistance
The Global Antibiotic Research and Development Partnership (GARDP) welcomes the recent declaration by the G7 health ministers, which commits to national and international efforts to tackle rising Antimicrobial Resistance (AMR).
The G7 ministers signaled strong support for GARDP’s pivotal work. They underlined “the importance of closing GARDP’s funding gap to advance GARDP’s 5by5 initiative to deliver five new treatments by 2025”.
The G7 Health Ministers Declaration also welcomed the antibiotics access initiative, SECURE, co-developed by GARDP and the World Health Organization (WHO) in collaboration with other international bodies, to expand access to essential antibiotics. These will include new antibiotics to treat drug-resistant infections, but also existing antibiotics that are not widely available, or face frequent supply chain interruptions and shortages.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.